Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2022 16:34 ET | Source: Klayman & Toskes P.A.

Oppenheimer/Horizon Investors Win Over $36 Million in FINRA Arbitration Case Following Alleged Ponzi Scheme

ATLANTA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The securities fraud law firm of KlaymanToskes continues to represent Oppenheimer (NYSE: OPY) customers in FINRA arbitration claims (Case No. 22-00866)...
December 03, 2021 18:46 ET | Source: Klayman & Toskes P.A.

Notice to Current and Former Delta Air Lines Pilots: National Investor Fraud Law Firm KlaymanToskes Is Preparing to File a FINRA Arbitration Claim on Behalf of Former Delta Pilot Against Oppenheimer & Co. for Horizon Private Equity III Ponzi Losses

ATLANTA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- National investor fraud law firm KlaymanToskes (“KT”) announces it is preparing to file a FINRA arbitration claim against Oppenheimer & Co. (NYSE: OPY)...
October 08, 2021 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
February 11, 2020 16:01 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
March 18, 2019 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference

CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 13, 2018 09:05 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Pricing of $37.5 Million Public Offering

CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
December 12, 2018 16:01 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...